Deutsche Bank raises Bayer stock price target on stronger earnings

Deutsche Bank raised its price target on Bayer AG to EUR65.00 from EUR60.00, maintaining a Buy rating. The firm increased its 2026 adjusted EBITDA forecast to EUR10,060 million, driven by stronger pharmaceutical performance. Bayer's stock has surged 109% over the past year, trading at $15.91. The company reported Q3 2026 earnings of $0.0868 per share on revenue of $11.26 billion, missing expectations but raising full-year guidance.

Original reporting
Published Nov 10, 2026, 5:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 5:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BAYN.DE
Bullish
high confidence
Mentioned
$BAYN.DE
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BAYN.DEBullishMed
01

Why it matters

The higher target and improved forecasts could attract buying interest, especially in the pharma segment, while crop‑science headwinds remain a risk.

02

Market read

Analyst upgrade on a large-cap European ADR may influence short‑term price action and sector sentiment.

03

What to watch

Litigation cash outflows and pending glyphosate settlement could weigh on Bayer despite the upgrade.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Deutsche Bank's analyst team revised Bayer's valuation after the company reported stronger third‑quarter performance and raised its 2026‑2028 EBITDA guidance.

Company-level read

Ticker impact

$BAYN.DEBullishHigh confidence
Context

Deutsche Bank raised Bayer's price target to EUR65 from EUR60, citing stronger earnings and upgraded 2026‑2028 EBITDA forecasts.

Expected impact

likely upward pressure as investors price in the higher target and improved guidance

Evidence & confidence

The target raise reflects better-than-expected pharma performance and higher EBITDA multiples, which typically drive buying interest.

Market effects

Pharma sector may see modest rally as Bayer's upgraded outlook lifts peer sentiment.

European markets could benefit from the positive news on a major German conglomerate.

Limited to investors tracking large-cap healthcare stocks and ADRs.

Counterpoint

The upgrade may be premature if crop division challenges persist, potentially capping upside.

Key entities

  • Bayer AG

    German life‑science and agricultural chemicals group.

  • Deutsche Bank

    Investment bank providing the analyst upgrade.

Related articles

$BAYN.DEHighAI 8/10

Bayer’s $7.25 Billion Roundup Settlement Approved by US Judge

A Missouri judge approved Bayer AG's $7.25 billion settlement to resolve U.S. lawsuits linking Roundup weedkiller to cancer. The German company inherited the legal issues from its 2018 acquisition of Monsanto, which caused its stock to drop about 80% before recent legal wins. The case is Randall King v. Monsanto, Missouri Circuit Court Twenty-Second Judicial District (St. Louis).